Project Grant W81XWH1910040

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to understand the role of the STAT5 signaling pathway in tumor-associated macrophages and its impact on breast cancer growth and metastasis. The $499,744 award to the Regents of the University of Minnesota will fund studies using genetic mouse models to define the effects of deleting the STAT5 gene in macrophages on mammary tumor progression. The research will also identify...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $180,632 to the University of Pittsburgh to conduct research aimed at discovering and validating compounds that can block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, and to unravel the role of this cancer cell-MSC engulfment process in breast cancer metastasis. The key products and services to be delivered under this 2-year award include: 1) Optimizing a...

This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $569,441 in funding to the University of Wisconsin System for a 5-year research project. The project aims to investigate the mechanisms by which the p53-phosphoinositide (PI) signaling complex regulates nuclear activation of the AKT pathway, with a focus on how this signaling is differentially activated in wild-type versus mutant p53 cancer cells. Key objectives include...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate the role of the protein PlexinB2 in the formation of circulating tumor cell (CTC) clusters and their interaction with immune cells. The $545,983 award to Northwestern University, with a sub-award to Tufts Medical Center, aims to determine the clinical relevance of the PlexinB2 pathway in triple-negative breast cancer, elucidate the molecular mechanisms...

The National Cancer Institute (NCI) awarded a 5-year, $564,695 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center to study a new driver and therapeutic vulnerability of bone metastasis. The research aims to investigate the role of acyl-CoA binding protein (ACBP) in regulating lipid metabolism and promoting breast cancer bone metastasis. Specifically, the project will examine how ACBP stimulates fatty acid oxidation and protects against...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. to investigate the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The research aims to elucidate how the metabolic enzyme PFKFB4 regulates genetic and metabolic plasticity in the hypoxic tumor microenvironment, and how these adaptations impact immune suppression and metastatic...

This Project Grant award of $521,240 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) aims to identify critical events within the premetastatic niche that facilitate breast cancer metastasis. The research team at Purdue University, with a sub-award to the University of Iowa, will use an engineered model of the premetastatic niche to understand how specific changes, such as in the extracellular matrix composition and extracellular vesicles, make distant tissues...

This Project Grant award of $250,277 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program will support research investigating the role of the G-protein coupled estrogen receptor (GPER) on cancer-associated fibroblasts (CAFs) in driving therapy-resistant estrogen receptor positive (ER+) breast cancer progression. The research strategy aims to: 1) identify how GPER signaling in CAFs regulates biophysical/biochemical cues and how GPER-mediated matrix...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...

This Project Grant award of $500,681, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program, supports research on the role of phosphorylation of alpha- and beta-tubulin as a "toggle switch" governing cancer-related phenotypes in human breast cancer cells. The research aims to establish a novel framework for assessing metastatic potential and explore improved strategies for breast cancer...